Robert Burns, an analyst from H.C. Wainwright, reiterated the Buy rating on OnKure Therapeutics. The associated price target was lowered to $34.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Robert Burns has given his Buy rating due to a combination of factors surrounding OnKure Therapeutics’ promising developments. The company’s lead candidate, OKI-219, is showing potential in its ongoing clinical trials. Despite the absence of objective responses so far, the drug has demonstrated favorable pharmacokinetics and a strong safety profile, which suggests it could be suitable for combination therapies.
Furthermore, OnKure is planning to release updated and initial results from various trials in early 2026, which could provide further insights into the drug’s efficacy. The company’s strategic focus on expanding OKI-219’s application beyond oncology into treating vascular malformations also adds to its potential growth. These elements, combined with the competitive landscape heating up, position OnKure Therapeutics as a compelling investment opportunity.
According to TipRanks, Burns is an analyst with an average return of -2.6% and a 41.25% success rate. Burns covers the Healthcare sector, focusing on stocks such as Exelixis, Replimune Group, and Cullinan Management.
In another report released on November 7, LifeSci Capital also maintained a Buy rating on the stock with a $21.00 price target.